Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes. At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other. We are committed to building an open, diverse, and inclusive culture for all employees.
| Website | http://www.outpacebio.com |
| Revenue | $6.4 million |
| Employees | 73 (58 on RocketReach) |
| Founded | 2020 |
| Address | 700 Dexter Ave N Suite 300, Seattle, Washington 98109, US |
| Phone | +1 317-272-3600 |
| Technologies |
JavaScript
,
HTML
,
Twitter
+10 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Cell Therapy, Protein Design, Cellular Engineering, Solid Tumor Treatment, Oncology Therapeutics, Cancer Treatment, Immunotherapy, Regenerative Medicine, Biotechnology, Pharmaceutical Research, Drug Development, Clinical Trials, Precision Medicine, Gene Therapy, Cell Engineering, Therapeutic Proteins, Cancer Research, Biopharmaceutical, Medical Research, Life Sciences |
| Competitors | Amgen, Regeneron, BioMarin Pharmaceutical Inc., Beam Therapeutics, Intellia Therapeutics, Inc., Spark Therapeutics, Inc., CRISPR Therapeutics, Editas Medicine, Sangamo Therapeutics, Inc., Audentes Therapeutics +47 more (view full list) |
Looking for a particular Outpace Bio employee's phone or email?
The Outpace Bio annual revenue was $6.4 million in 2026.
Marc Lajoie is the Co-founder, Chief Executive Officer of Outpace Bio.
58 people are employed at Outpace Bio.
Outpace Bio is based in Seattle, Washington.